Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
08/19/2009
Trade Name:
HIBERIX
Generic or Proper Name (*):
Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) *
Indications Studied:
Active immunization as a booster dose for the prevention of invasive disease caused by Haemophilus influenzae type b
Therapeutic Category:
Preventive Vaccine
Ages Studied:
15 -19 months
Study #:
1
Study Type:
Immunogenicity
Study Design:
Open Label
No Patients:
64
No Centers:
4
No Countries:
1
BPCA(B), PREA(P):
P
-
-